Multi-Epitope mRNA-LNP Vaccine Platform: Reprogramming Antigen Presentation Pathways and Mapping T Cell Cytotoxic Landscape within the Tumor Microenvironment of ICI-Refractory Esophageal Squamous Cell Carcinoma
Background: Overcoming the Resistance Barrier of Immune Checkpoint Inhibitor Monotherapy and Addressing the Bottleneck of Tumor Antigen Heterogeneity in Esophageal Squamous Cell Carcinoma Research and Development
Esophageal squamous cell carcinoma (ESCC) is a disease with significant unmet medical needs, characterized by a stagnant 5-year survival rate of 15-25% among global squamous cell malignancies. Treatment with PD-1/PD-L1 immune checkpoint inhibitors (ICIs) such as nivolumab and pembrolizumab yields objective response rates (ORRs) of only 15-30%, and acquired resistance within 12 months represents a critical challenge. Existing static, single-biomarker-guided approaches fail to address the in silico control of immune-suppressive myeloid-derived suppressor cells (MDSCs) accumulation, regulatory T cell (Treg) feedback flux, and HLA downregulation-mediated antigen presentation pathway disruption within the tumor microenvironment (TME), leading to an accumulation of data barriers that prevent the maintenance of effective cytotoxic T lymphocyte (CTL) engraftment. In particular, the extreme HLA polymorphism observed among ESCC patients poses a significant challenge, as single neoantigen-based personalized vaccine strategies are hindered by manufacturing lead times, batch effects, and cost barriers, effectively preventing their widespread industrial application.
Discovery: Dual TCGA/GTEx Transcriptome Tensor Operation and Real-World Validation of HLA Coverage in a Cohort of 132 Patients
IPM514 is a universal vaccine platform designed by dual cross-filtering TCGA tumor and GTEx normal tissue transcriptome matrices to select 15 epitope fragments from 9 tumor-associated antigens (TAAs) and integrating them into a lipid nanoparticle (LNP)-encapsulated multi-epitope mRNA cassette. In a cohort of 132 ESCC patients, IPM514 achieves HLA subtype coverage of over 50%, significantly surpassing the patient-specific manufacturing dependency of conventional single neoantigen vaccines. Stimulation of peripheral blood mononuclear cells (PBMCs) from healthy donors and ESCC patients with IPM514 results in significant expansion of antigen-specific CD8⁺ T cells, and the expanded CTLs demonstrate cross-reactivity against ESCC as well as head and neck and lung squamous cell carcinomas sharing similar antigen profiles, thereby elucidating the downstream transcriptomic network topological universality. Molecular integrity is ensured through the achievement of tumor growth inhibition, prolonged survival, and sustained immune protection in HLA-transgenic mouse models.
PD-1 Combination Therapy for TME Reprogramming and Establishment of a Precise, Layered Model of Reversible Immune Homeostasis
Combination therapy with IPM514 and anti-PD-1 antibodies enhances CD8⁺ T cell and dendritic cell infiltration within the tumor microenvironment and upregulates MHC-I antigen presentation pathways, demonstrating a phenotypic shift from an immune-suppressive to an immune-active TME. This provides a basis for precision stratification of patients based on omics matrices and establishes a framework for deriving biomarker signatures that can predict response to vaccine combination therapy even in ICI-refractory patients. A framework is established for simultaneously downregulating the Treg/MDSC suppression axis and upregulating the effector T cell activation axis, enabling the autonomous maintenance of effective antitumor homeostasis even under aberrant immune tolerance stress.
Outlook: Establishing a Standard for Programmable Tumor Immunology and Launching a Digital Governance System for Next-Generation mRNA Vaccine IND
This platform represents a paradigm shift in ESCC immunotherapy R&D governance, moving from a static, retrospective approach to a proactive, AI-driven, multidimensional transcriptome tensor-based programmable antigen selection infrastructure. With global mRNA cancer vaccine pipelines such as BioNTech's BNT111 (melanoma Phase II, NCT04526899) and Moderna's mRNA-4157/V940 (melanoma Phase III, co-developed with Merck, 2025 AACR data update) projected to expand to a $25 billion market by 2030, the universal multi-epitope design of IPM514 establishes a computational moat that eliminates batch-to-batch variations in patient-specific manufacturing. By linking genetic gradient correction coefficients in high-throughput HLA typing screening, the platform effectively eliminates false-positive epitopes and functions as a master asset that drastically shortens the timeline for meeting digital companion diagnostic (CDx) standards and obtaining IND approval.
Esophageal squamous cell carcinoma (ESCC) has limited treatment options post-immune checkpoint inhibitor (ICI) resistance. We developed IPM514, a universal multi-epitope mRNA lipid nanoparticle (LNP) vaccine targeting tumor-associated antigens identified via transcriptomic analysis of TCGA/GTEx datasets and validated in 132 ESCC patients. IPM514 contains 15 fragments from 9 antigens, covering most patients and over half of HLA subtypes. Peripheral blood mononuclear cells (PBMCs) from healthy donors and ESCC patients stimulated with IPM514 effectively expanded specific T cells that exhibited significant cytotoxic activity against ESCC and other squamous cell carcinomas with similar antigen profiles. In HLA-transgenic mouse models, IPM514 suppressed tumor growth, extended survival, and provided durable protection. Importantly, combination therapy with PD-1 blockade augmented antitumor efficacy by promoting immune cell infiltration, upregulating antigen presentation pathways, and reprogramming the tumor microenvironment toward an anti-tumorigenic state. These results demonstrate IPM514 represents a promising novel mRNA vaccine strategy for improving ESCC immunotherapy.
The universal multi-epitope mRNA-LNP vaccine design of this study transcends theoretical explorations of tumor immunology and directly translates into a tangible global supply chain for finished pharmaceuticals and a next-generation precision medicine business line for cancer immunotherapy.
First, in the clinical setting, it instantaneously scans the CTL responsiveness kinetics of ICI-refractory ESCC patients using a PBMC-based immune monitoring algorithm, eliminating the temporal noise associated with the time to unresponsiveness and securing a therapeutic window.
Simultaneously, by linking to an open-source database comprising large-scale TCGA/GTEx omics matrices, the platform enables virtual simulations of confounding HLA mismatches during clinical trial design and real-time reverse calculation of the effective binding free energy of epitope-MHC complexes, thereby realizing a companion diagnostic (CDx) panel interface.
Furthermore, by linking HLA subtype-specific epitope coverage rates as correction coefficients during the large-scale clinical trials of multinational corporations' next-generation squamous cell carcinoma immunotherapies, the platform eliminates batch-to-batch variations in antigen composition and functions as a backbone infrastructure that maximizes the probability of obtaining clinical trial protocol and cGMP commercial manufacturing approvals from global regulatory agencies.